Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
IFNW1 Biologics Sequence Review Report 2026: Interferon omega-1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNW1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IFNA7 Biologics Sequence Review Report 2026: Interferon alpha-7 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IFNL4 Biologics Sequence Review Report 2026: Interferon lambda-4 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNL4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IFNA8 Biologics Sequence Review Report 2026: Interferon alpha-8 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IFNA4 Biologics Sequence Review Report 2026: Interferon alpha-4 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IFNA2 Biologics Sequence Review Report 2026: Interferon alpha-2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IFNA21 Biologics Sequence Review Report 2026: Interferon alpha-21 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA21 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IFI30 Biologics Sequence Review Report 2026: Gamma-interferon-inducible lysosomal thiol reductase Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFI30 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IFNA17 Biologics Sequence Review Report 2026: Interferon alpha-17 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IFNA14 Biologics Sequence Review Report 2026: Interferon alpha-14 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA14 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CFH Biologics Sequence Review Report 2026: Complement factor H Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of CFH protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FZD9 Biologics Sequence Review Report 2026: Frizzled-9 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of FZD9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
2
3
4
5
>>
1670
>